Intellia Therapeutics (NASDAQ:NTLA) Hits New 1-Year Low - Should You Sell?

Intellia Therapeutics, Inc. (NASDAQ:NTLA - Get Free Report)'s share price reached a new 52-week low on Thursday . The stock traded as low as $16.25 and last traded at $16.65, with a volume of 389198 shares changing hands. The stock had previously closed at $19.94.

Analysts Set New Price Targets

NTLA has been the topic of several research reports. Evercore ISI upgraded shares of Intellia Therapeutics to a "strong-buy" rating in a research report on Friday, August 9th. Canaccord Genuity Group restated a "buy" rating and set a $73.00 price objective on shares of Intellia Therapeutics in a research report on Thursday, June 27th. Stifel Nicolaus lowered their price objective on shares of Intellia Therapeutics from $80.00 to $64.00 and set a "buy" rating on the stock in a research report on Wednesday, September 11th. Chardan Capital lowered their price objective on shares of Intellia Therapeutics from $94.00 to $88.00 and set a "buy" rating on the stock in a research report on Thursday. Finally, JPMorgan Chase & Co. decreased their target price on shares of Intellia Therapeutics from $61.00 to $55.00 and set an "overweight" rating on the stock in a research report on Monday, August 12th. One analyst has rated the stock with a sell rating, four have assigned a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $63.64.

Intellia Therapeutics Trading Down 20.5 %

The firm has a market cap of $1.53 billion, a P/E ratio of -2.96 and a beta of 1.76. The business's fifty day simple moving average is $20.84 and its 200-day simple moving average is $22.82.

Intellia Therapeutics (NASDAQ:NTLA - Get Free Report) last announced its quarterly earnings results on Thursday, August 8th. The company reported ($1.52) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.23) by ($0.29). The business had revenue of $7.00 million for the quarter, compared to analyst estimates of $19.68 million. The firm's revenue was down 48.5% on a year-over-year basis. During the same quarter in the previous year, the business posted ($1.40) earnings per share. Analysts anticipate that Intellia Therapeutics, Inc. will post -5.22 earnings per share for the current year.

Insiders Place Their Bets

In other news, CAO Michael P. Dube sold 2,012 shares of Intellia Therapeutics stock in a transaction dated Wednesday, October 2nd. The shares were sold at an average price of $19.01, for a total transaction of $38,248.12. Following the sale, the chief accounting officer now owns 47,012 shares of the company's stock, valued at approximately $893,698.12. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 3.00% of the company's stock.

Institutional Investors Weigh In On Intellia Therapeutics

Large investors have recently modified their holdings of the stock. Blue Trust Inc. boosted its stake in shares of Intellia Therapeutics by 1,664.3% during the 2nd quarter. Blue Trust Inc. now owns 1,482 shares of the company's stock valued at $33,000 after purchasing an additional 1,398 shares in the last quarter. EverSource Wealth Advisors LLC boosted its stake in shares of Intellia Therapeutics by 763.5% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 1,753 shares of the company's stock valued at $39,000 after purchasing an additional 1,550 shares in the last quarter. Eastern Bank bought a new stake in Intellia Therapeutics during the third quarter worth about $41,000. Values First Advisors Inc. bought a new stake in Intellia Therapeutics during the third quarter worth about $54,000. Finally, First Horizon Advisors Inc. boosted its stake in Intellia Therapeutics by 22.1% during the second quarter. First Horizon Advisors Inc. now owns 2,604 shares of the company's stock worth $58,000 after acquiring an additional 472 shares in the last quarter. Institutional investors own 88.77% of the company's stock.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.